Toshitaka Okabe

Dr. Toshitaka Okabe


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2017 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
TOToshitaka Okabe
Toshitaka Okabe
TYTadayuki Yakushiji
Tadayuki Yakushiji
TKTakehiko Kido
Takehiko Kido
YOYuji Oyama
Yuji Oyama
WIWataru Igawa
Wataru Igawa
MOMasahiko Ochiai
Masahiko Ochiai
Few studies have reported the impact of high-dose loop diuretics at discharge on prognosis in Japanese patients with heart failure (HF). Our purpose was to assess the relationship between the dose of loop diuretics at discharge and cardiovascular mortality in patients with HF. We enrolled decompensated HF patients who were admitted to our hospital between March 2010 and March 2015, and compared HF patients who received high-dose loop diuretics at discharge (HD group) with low-dose loop diuretics at discharge (LD group) with regard to risk of cardiovascular mortality, and all-cause mortality. High-dose loop diuretic was defined as ≥40 mg/day of oral furosemide at discharge. A total of 215 patients were enrolled to the study. The median follow-up duration was 641 days. All-cause and cardiovascular mortality were significantly lower in the LD group than in the HD group (10.4% vs. 31.6%, P < 0.001; 2.2% vs. 24.6%, P < 0.001, respectively). High-dose loop diuretics were associated with cardiovascular mortality in multivariate Cox proportional hazards model (hazard ratio, 16.06, 95% confidence interval 3.457 to 116.8; P < 0.001). The largest area under the receiver operating characteristic curve (0.85) for cardiovascular death was obtained with a threshold of 40 mg furosemide. High-dose loop diuretic use at discharge was one of the predictors of cardiovascular mortality in patients with HF. An oral furosemide dose of 40 mg daily may be defined as ‘high-dose’ loop diuretics in Japanese patients with chronic HF.

4 July 2016 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
TOToshitaka Okabe
Toshitaka Okabe
TYTadayuki Yakushiji
Tadayuki Yakushiji
MHMichiaki Hiroe
Michiaki Hiroe
YOYuji Oyama
Yuji Oyama
WIWataru Igawa
Wataru Igawa
MOMasahiko Ochiai
Masahiko Ochiai
A 32-year-old man presented with palpitation. He was diagnosed with pulmonary sarcoidosis by lung biopsy. The electrocardiogram showed first-degree atrioventricular block and complete right bundle branch block (CRBBB). We planned to examine laboratory data, echocardiography, Holter monitoring, and gallium-67 scintigraphy. Before he went through all these exams, he developed ventricular tachycardia. After defibrillation was performed, his electrocardiogram revealed complete atrioventricular block. We observed elevation of serum angiotensin-converting enzyme levels. In addition, both of gallium-67 scintigraphy and 18F-fluorodeoxyglucose positron emission tomography showed abnormal uptake in the ventricular septum. We diagnosed the patient with cardiac sarcoidosis associated with these arrhythmias. We started treatment with methylprednisolone pulse therapy (1 g daily). After 3 days of steroid pulse therapy, we administered prednisolone 30 mg daily. On day 15, electrocardiogram changed from complete atrioventricular block to first-degree atrioventricular block and CRBBB. He was discharged with no progression with cardiac sarcoidosis for 2 years.

1 March 2017 in International Journal of Cardiology
Verified
Journal Article
Closed access
TOToshitaka Okabe
Toshitaka Okabe
TYTadayuki Yakushiji
Tadayuki Yakushiji
TKTakehiko Kido
Takehiko Kido
YOYuji Oyama
Yuji Oyama
WIWataru Igawa
Wataru Igawa
MOMasahiko Ochiai
Masahiko Ochiai

9 July 2020 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
TOToshitaka Okabe
Toshitaka Okabe
TYTadayuki Yakushiji
Tadayuki Yakushiji
TKTakehiko Kido
Takehiko Kido
TKTaro Kimura
Taro Kimura
YAYu Asukai
Yu Asukai
MOMasahiko Ochiai
Masahiko Ochiai
Aims Our purpose was to investigate the association between the B‐type natriuretic peptide (BNP) level at discharge, the occurrence of worsening renal function (WRF), and long‐term outcomes in patients with heart failure (HF). Methods and results We enrolled hospitalized acute HF patients. We divided patients into four groups on the basis of BNP <250 pg/mL (BNP−) or BNP ≥250 pg/mL (BNP+) at discharge and the occurrence of WRF during admission: BNP−/WRF−, BNP−/WRF+, BNP+/WRF−, and BNP+/WRF+. We evaluated the association between BNP at discharge, WRF, and cardiovascular/all‐cause mortality/hospitalization due to HF. Clinical follow‐up was completed in 301 patients. At discharge, percentages of the patients with clinical signs of HF were low and similar among four groups. The median follow‐up period was 1206 days (interquartile range, 733–1825 days). The composite endpoint of cardiovascular mortality and HF hospitalization was significantly different between the four groups [12.9% (BNP−/WRF−), 22.7% (BNP−/WRF+), 35.8% (BNP+/WRF−), and 55.4% (BNP+/WRF+), P < 0.0001]. All‐cause mortality was also different etween the four groups (15.1%, 38.6%, 28.7%, and 39.3%, respectively, P = 0.003). In the multivariate Cox proportional hazards model, the combination of BNP ≥250 pg/mL and WRF showed the highest hazard ratio (HR) for composite endpoint (HR, 5.201; 95% confidence interval, 2.582–11.11; P < 0.0001), and BNP−/WRF+ was associated with increased all‐cause mortality (HR, 2.286; 95% confidence interval, 1.089–4.875; P = 0.03). Patients in BNP+/WRF+ had a higher cardiovascular mortality (28.6%), and those in BNP−/WRF+ had a high non‐cardiovascular mortality (29.5%). Conclusions Heart failure patients with BNP ≥250 pg/mL at discharge and in‐hospital occurrence of WRF had the highest risk for the composite endpoint (cardiovascular mortality and HF hospitalization) among groups.

1 January 1990 in Journal of Histochemistry & Cytochemistry
Verified
Journal Article
Open access
MFMasashi Fukayama
Masashi Fukayama
NFN Funata
N Funata
YHYukiko K Hayashi
Yukiko K Hayashi
YMY Maeda
Y Maeda
MKM Koike
M Koike
TOToshitaka Okabe
Toshitaka Okabe
Expression of brain-associated small-cell lung cancer antigen (BASCA) in developing lung and in lung tumors was investigated immunohistochemically and immunoelectron microscopically with monoclonal antibodies recognizing different epitopes of BASCA. In fetal lung, epithelial and mesenchymal cells had different spatial and temporal expression patterns, in contrast to the consistent pattern in neural cells. The cell membranes of epithelial cells of the proximal bronchial tubes were diffusely positive at the pseudoglandular stage. Ciliated cells lost immunoreactivity shortly after their emergence, but non-ciliated cells, including endocrine cells, lost it at the alveolar stage. The immunoreactivity in mesenchymal cells was reduced in the proximal airway, but positivity remained in the distal lung later during the postnatal period. All endocrine tumors of the lung, defined by diffuse synaptophysin immunoreactivity, expressed BASCA, but some non-endocrine carcinomas which also lacked densely cored granules ultrastructurally, showed BASCA positivity. The temporal and spatial pattern of BASCA expression in the developing lung suggests that BASCA plays an active role in lung morphogenesis. BASCA may be expressed as an oncofetal substance in some non-endocrine carcinomas of the lung.

11 September 2015 in Cardiovascular Therapeutics
Verified
Journal Article
Closed access
TOToshitaka Okabe
Toshitaka Okabe
TYTadayuki Yakushiji
Tadayuki Yakushiji
WIWataru Igawa
Wataru Igawa
MOMorio Ono
Morio Ono
TKTakehiko Kido
Takehiko Kido
MOMasahiko Ochiai
Masahiko Ochiai